Anixa Biosciences Inc. sell mixitrader
Start price
09.12.23
/
50%
€3.78
Target price
09.12.24
€1.00
Performance (%)
-7.41%
End price
23.12.23
€3.50
Summary
This prediction ended on 23.12.23 with a price of €3.50. With a performance of -7.41%, the SELL prediction by mixitrader was trending in the right direction. mixitrader has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Anixa Biosciences Inc. | - | - |
iShares Core DAX® | 1.665% | 1.692% |
iShares Nasdaq 100 | -0.475% | 1.483% |
iShares Nikkei 225® | 2.620% | 4.475% |
iShares S&P 500 | -0.091% | 1.099% |
According to mixitrader what are the pros and cons of Anixa Biosciences Inc. for the foreseeable future?
Pros
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Standard Investments for future growth
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Sustainability is important
Medium risks for its business
High dividend yield expected
positive Cash Flow expected
Good rating
ROE higher than 10% per year
Capable Management
Good culture
Differentiated customer and product portfolio
Growths faster than the competition
Stable Large shareholder and/or long term investor
Top 10 in its market
Small cyclical dependencies
Known brand
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Valuable balance sheet
Cons
Comments by mixitrader for this prediction
In the thread Anixa Biosciences Inc. diskutieren
Sell mit Kursziel 1,0
In the thread Trading Anixa Biosciences Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by mixitrader for Anixa Biosciences Inc.
Anixa Biosciences Inc.
Start price
Target price
Perf. (%)
€3.38
16.03.24
16.03.24
€6.00
16.03.25
16.03.25
-5.92%
30.03.24
30.03.24
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Anixa Biosciences Inc.
Start price
Target price
Perf. (%)
€5.42
17.09.22
17.09.22
€2.00
17.09.23
17.09.23
-4.61%
01.10.22
01.10.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation